| [1] |
Owen RG,Treon SP,Al-Katib A,et al.Clinicopathological definition of Waldenstrom’s macroglobulinemia:consensus panel recommendations from the Second International Workshop on Waldenstrom’s Macroglobulinemia[J].Semin Oncol,2003,30(2):110-115.
|
| [2] |
Treon SP,Xu L,Yang G,et al.MYD88 L265P somatic mutation in Waldenstrom’s macroglobulinemia[J].N Engl J Med,2012,367(9):826-833.
|
| [3] |
Hunter ZR,Xu L,Yang G,et al.The genomic landscape of Waldenstrom macroglobulinemia is characterized by highly recurring MYD88 and WHIM-like CXCR4 mutations,and small somatic deletions associated with B-cell lymphomagenesis[J].Blood,2014,123(11):1637-1646.
|
| [4] |
Maglione PJ,Simchoni N,Cunningham-Rundles C.Toll-like receptor signaling in primary immune deficiencies[J].Ann N Y Acad Sci,2015,1356(11):1-21.
|
| [5] |
Yang G,Zhou Y,Liu X,et al.A mutation in MYD88(L265P) supports the survival of lymphoplasmacytic cells by activation of Bruton tyrosine kinase in Waldenstrom macroglobulinemia[J].Blood,2013,122(7):1222-1232.
|
| [6] |
Rossi D.Role of MYD88 in lymphoplasmacytic lymphoma diagnosis and pathogenesis[J].Hematology Am Soc Hematol Educ Program,2014,2014(1):113-118.
|
| [7] |
von Bernuth H,Picard C,Puel A,et al. Experimental and natural infections in MyD88-and IRAK-4-deficient mice and humans[J].Eur J Immunol,2012,42(12):3126-3135.
|
| [8] |
Xu L,Hunter ZR,Yang G,et al.Detection of MYD88 L265P in peripheral blood of patients with Waldenstrom’s macroglobulinemia and IgM monoclonal gammopathy of undetermined significance[J].Leukemia,2014,28(8):1698-1704.
|
| [9] |
Ansell SM,Hodge LS,Secreto FJ,et al.Activation of TAK1 by MYD88 L265P drives malignant B-cell growth in non-Hodgkin lymphoma[J].Blood Cancer Journal,2014,4(2):e183.
|
| [10] |
Gachard N,Parrens M,Soubeyran I,et al.IGHV gene features and MYD88 L265P mutation separate the three marginal zone lymphoma entities and Waldenstrom macroglobulinemia/lymphoplasmacytic lymphomas[J].Leukemia,2013,27(1):183-189.
|
| [11] |
Varettoni M,Arcaini L,Zibellini S,et al.Prevalence and clinical significance of the MYD88(L265P) somatic mutation in Waldenstrom’s macroglobulinemia and related lymphoid neoplasms[J].Blood,2013,121(13):2522-2528.
|
| [12] |
Xu L,Hunter ZR,Yang G,et al.MYD88 L265P in Waldenstrom macroglobulinemia,immunoglobulin M monoclonal gammopathy,and other B-cell lymphoproliferative disorders using conventional and quantitative allele-specific polymerase chain reaction[J].Blood,2013,121(11):2051-2058.
|
| [13] |
Jimenez C,Sebastian E,Chillon MC,et al.MYD88 L265P is a marker highly characteristic of,but not restricted to,Waldenstrom’s macroglobulinemia[J].Leukemia,2013,27(8):1722-1728.
|
| [14] |
Moller C,Stromberg T,Juremalm M,et al.Expression and function of chemokine receptors in human multiple myeloma[J].Leukemia,2003,17(1):203-210.
|
| [15] |
Roccaro AM,Sacco A,Jimenez C,et al.C1013G/CXCR4 acts as a driver mutation of tumor progression and modulator of drug resistance in lymphoplasmacytic lymphoma[J].Blood,2014,123(26):4120-4131.
|
| [16] |
Hernandez PA,Gorlin RJ,Lukens JN,et al.Mutations in the chemokine receptor gene CXCR4 are associated with WHIM syndrome,a combined immunodeficiency disease[J].Nat Genet,2003,34(1):70-74.
|
| [17] |
Ngo HT,Leleu X,Lee J,et al.SDF-1/CXCR4 and VLA-4 interaction regulates homing in Waldenstrom macroglobulinemia[J].Blood,2008,112(1):150-158.
|
| [18] |
Cao Y,Hunter ZR,Liu X,et al.CXCR4 WHIM-like frameshift and nonsense mutations promote ibrutinib resistance but do not supplant MYD88(L265P)-directed survival signalling in Waldenstrom macroglobulinaemia cells[J].Br J Haematol,2015,168(5):701-707.
|
| [19] |
Xu L,Hunter ZR,Tsakmaklis N,et al.Clonal architecture of CXCR4 WHIM-like mutations in Waldenstrom macroglobulinaemia[J].Br J Haematol,2016,172(5):735-744.
|
| [20] |
Scala S.Molecular pathways:targeting the CXCR4-CXCL12 axis-untapped potential in the tumor microenvironment[J].Clin Cancer Res,2015,21(19):4278-4285.
|
| [21] |
Treon SP,Cao Y,Xu L,et al.Somatic mutations in MYD88 and CXCR4 are determinants of clinical presentation and overall survival in Waldenstrom macroglobulinemia[J].Blood,2014,123(18):2791-2796.
|
| [22] |
Poulain S,Roumier C,Venet-Caillault A,et al.Genomic landscape of CXCR4 mutations in Waldenstrom macroglobulinemia[J].Clin Cancer Res,2016,22(6):1480-1488.
|
| [23] |
Varettoni M,Zibellini S,Arcaini L,et al.MYD88(L265P) mutation is an independent risk factor for progression in patients with IgM monoclonal gammopathy of undetermined significance[J].Blood,2013,122(13):2284-2285.
|
| [24] |
Kyle RA,Therneau TM,Rajkumar SV,et al.Long-term follow-up of IgM monoclonal gammopathy of undetermined significance[J].Blood,2003,102(10):3759-3764.
|
| [25] |
Owen RG,Pratt G,Auer RL,et al.Guidelines on the diagnosis and management of Waldenstr?m macroglobulinaemia[J].Br J Haematol,2014,165(3):316-333.
|
| [26] |
Grunenberg A,Buske C.Waldenstrom’s macroglobulinemia:current developments in diagnostics and therapy[J].Internist(Berl),2016,57(3):238-244.
|
| [27] |
Treon SP.How I treat Waldenstrom macroglobulinemia[J].Blood,2015,126(6):721-732.
|
| [28] |
Chakraborty R,Kapoor P,Ansell SM,et al.Emerging therapeutic options for Waldenstrom macroglobulinemia/lymphoplasmacytic lymphoma[J].Expert Rev Anticancer Ther,2015,15(10):1143-1156.
|
| [29] |
Treon SP,Tripsas CK,Meid K,et al.Ibrutinib in previously treated Waldenstrom’s macroglobulinemia[J].N Engl J Med,2015,372(15):1430-1440.
|
| [30] |
Cao Y,Hunter ZR,Liu X,et al.The WHIM-like CXCR4(S338X) somatic mutation activates AKT and ERK,and promotes resistance to ibrutinib and other agents used in the treatment of Waldenstrom’s macroglobulinemia[J].Leukemia,2015,29(1):169-176.
|
| [31] |
Dale DC,Bolyard AA,Kelley ML,et al.The CXCR4 antagonist plerixafor is a potential therapy for myelokathexis,WHIM syndrome[J].Blood,2011,118(18):4963-4966.
|
Acta Academiae Medicinae Sinica
)
